EA201892212A1 - Фармацевтическая композиция, которая включает поверхностные и нуклеокапсидные антигены вируса гепатита b - Google Patents
Фармацевтическая композиция, которая включает поверхностные и нуклеокапсидные антигены вируса гепатита bInfo
- Publication number
- EA201892212A1 EA201892212A1 EA201892212A EA201892212A EA201892212A1 EA 201892212 A1 EA201892212 A1 EA 201892212A1 EA 201892212 A EA201892212 A EA 201892212A EA 201892212 A EA201892212 A EA 201892212A EA 201892212 A1 EA201892212 A1 EA 201892212A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- virus
- composition
- pharmaceutical composition
- hepatitis
- antigen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2016000038A CU24454B1 (es) | 2016-03-31 | 2017-03-14 | Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b |
| PCT/CU2017/050001 WO2017167317A1 (es) | 2016-03-31 | 2017-03-14 | Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201892212A1 true EA201892212A1 (ru) | 2019-03-29 |
Family
ID=58671308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201892212A EA201892212A1 (ru) | 2016-03-31 | 2017-03-14 | Фармацевтическая композиция, которая включает поверхностные и нуклеокапсидные антигены вируса гепатита b |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11491218B2 (enExample) |
| EP (1) | EP3437654B1 (enExample) |
| JP (1) | JP6981992B2 (enExample) |
| KR (1) | KR20180125985A (enExample) |
| CN (1) | CN109219449B (enExample) |
| AR (1) | AR108009A1 (enExample) |
| AU (1) | AU2017243136B2 (enExample) |
| BR (1) | BR112018069738A2 (enExample) |
| CA (1) | CA3017778A1 (enExample) |
| CU (1) | CU24454B1 (enExample) |
| EA (1) | EA201892212A1 (enExample) |
| ES (1) | ES2965709T3 (enExample) |
| MX (1) | MX2018011793A (enExample) |
| MY (1) | MY202118A (enExample) |
| TW (1) | TWI755383B (enExample) |
| UA (1) | UA128952C2 (enExample) |
| WO (1) | WO2017167317A1 (enExample) |
| ZA (1) | ZA201806325B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020355020A1 (en) * | 2019-09-23 | 2022-04-28 | Ascendo Biotechnology, Inc. | Biodegradable nanocomplex vaccines, methods for suppression of hepapitis B virus replication and hepapitis B virus surface antigen secretion |
| CU20200028A7 (es) | 2020-04-20 | 2021-11-04 | Ct Ingenieria Genetica Biotecnologia | Nucleoproteína viral y formulaciones que la contienen |
| CN116218881B (zh) * | 2022-10-21 | 2024-08-13 | 山东大学 | 一种治疗或者预防乙肝病毒的疫苗 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22290A1 (es) | 1990-10-08 | 1995-01-31 | Cigb | Procedimiento para la obtencion de antigeno de superficie del virus de la hepatitis b de superior capacidad inmunoganica y su uso en un preparado vacunal |
| CU22871A1 (es) | 1998-12-02 | 2003-10-21 | Ct Ingenieria Genetica Biotech | Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal |
| CU23002A1 (es) * | 2000-12-01 | 2004-11-18 | Ct Ingenieria Genetica Biotech | Método de obtención de agregados antigénicos y su uso en formulaciones |
| CN1164331C (zh) * | 2001-05-23 | 2004-09-01 | 中国人民解放军第二军医大学 | 一种人乙型肝炎核酸疫苗 |
| CU23740A1 (es) | 2009-09-29 | 2011-12-28 | Ct Ingenieria Genetica Biotech | Método de obtención de una formulación de antígenos del virus de la hepatitis b |
| CN110859961A (zh) * | 2013-07-26 | 2020-03-06 | 复旦大学 | 病毒免疫治疗药物复合物在制备治疗hbv感染药物中的应用 |
-
2017
- 2017-03-14 EP EP17721509.2A patent/EP3437654B1/en active Active
- 2017-03-14 CN CN201780033618.XA patent/CN109219449B/zh active Active
- 2017-03-14 EA EA201892212A patent/EA201892212A1/ru unknown
- 2017-03-14 UA UAA201810715A patent/UA128952C2/uk unknown
- 2017-03-14 JP JP2018551333A patent/JP6981992B2/ja active Active
- 2017-03-14 AU AU2017243136A patent/AU2017243136B2/en not_active Ceased
- 2017-03-14 ES ES17721509T patent/ES2965709T3/es active Active
- 2017-03-14 WO PCT/CU2017/050001 patent/WO2017167317A1/es not_active Ceased
- 2017-03-14 MY MYPI2018703588A patent/MY202118A/en unknown
- 2017-03-14 US US16/088,188 patent/US11491218B2/en active Active
- 2017-03-14 CU CU2016000038A patent/CU24454B1/es unknown
- 2017-03-14 MX MX2018011793A patent/MX2018011793A/es unknown
- 2017-03-14 KR KR1020187028749A patent/KR20180125985A/ko not_active Ceased
- 2017-03-14 CA CA3017778A patent/CA3017778A1/en active Pending
- 2017-03-14 BR BR112018069738A patent/BR112018069738A2/pt active Search and Examination
- 2017-03-22 TW TW106109533A patent/TWI755383B/zh not_active IP Right Cessation
- 2017-03-30 AR ARP170100786A patent/AR108009A1/es not_active Application Discontinuation
-
2018
- 2018-09-20 ZA ZA2018/06325A patent/ZA201806325B/en unknown
-
2022
- 2022-03-08 US US17/689,581 patent/US11759517B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3437654B1 (en) | 2023-09-20 |
| ZA201806325B (en) | 2020-08-26 |
| HK1259329A1 (zh) | 2019-11-29 |
| MY202118A (en) | 2024-04-04 |
| CU20160038A7 (es) | 2017-11-07 |
| JP2019510064A (ja) | 2019-04-11 |
| ES2965709T3 (es) | 2024-04-16 |
| CN109219449B (zh) | 2022-08-30 |
| AR108009A1 (es) | 2018-07-04 |
| AU2017243136B2 (en) | 2022-02-17 |
| CU24454B1 (es) | 2019-11-04 |
| UA128952C2 (uk) | 2024-12-11 |
| WO2017167317A1 (es) | 2017-10-05 |
| US20220193228A1 (en) | 2022-06-23 |
| EP3437654A1 (en) | 2019-02-06 |
| US20200297840A1 (en) | 2020-09-24 |
| TWI755383B (zh) | 2022-02-21 |
| US11491218B2 (en) | 2022-11-08 |
| CN109219449A (zh) | 2019-01-15 |
| KR20180125985A (ko) | 2018-11-26 |
| CA3017778A1 (en) | 2017-10-05 |
| US11759517B2 (en) | 2023-09-19 |
| JP6981992B2 (ja) | 2021-12-17 |
| AU2017243136A1 (en) | 2018-10-11 |
| TW201735945A (zh) | 2017-10-16 |
| MX2018011793A (es) | 2018-12-17 |
| BR112018069738A2 (pt) | 2019-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202091513A1 (ru) | Вакцины против вируса гепатита b (hbv) и их применение | |
| PH12018500199A1 (en) | Antibodies that potently neutralize hepatitis b virus and uses thereof | |
| WO2017019891A3 (en) | Compositions and methods for silencing hepatitis b virus gene expression | |
| BR112018009009A8 (pt) | terapia combinada de um inibidor de formação de capsídeo hbv e um interferon | |
| WO2008103380A3 (en) | Hepatitis b virus compositions and methods of use | |
| PH12020550924A1 (en) | Heptatitis b virus (hbv) vaccines and uses thereof | |
| EA202192512A1 (ru) | Пиримидоновые производные с конденсированными кольцами для применения в лечении инфекции, вызванной hbv, или заболеваний, вызванных hbv | |
| EA201892212A1 (ru) | Фармацевтическая композиция, которая включает поверхностные и нуклеокапсидные антигены вируса гепатита b | |
| EA201500114A1 (ru) | Композиция антитела для предупреждения или лечения инфекции мутантным вирусом гепатита b | |
| HRP20240163T1 (hr) | Metode i pripravci za izazivanje zaštitnog imuniteta protiv infekcije filovirusom | |
| EA201290556A1 (ru) | Оральная лекарственная форма, включающая энтекавир | |
| JP2023012539A (ja) | 経鼻ｂ型肝炎ワクチン組成物およびその製造方法 | |
| JP2019510064A5 (enExample) | ||
| JP2016520077A5 (enExample) | ||
| WO2018066891A3 (ko) | 인터페론 베타 변이체의 안정화 제제 | |
| MX2022004869A (es) | Vacuna de particulas similares al virus chikungunya y metodos de uso de la misma. | |
| PH12020500194A1 (en) | Malaria vaccine | |
| MX2021005588A (es) | Composiciones inmunogenicas para el tratamiento de la hepatitis b. | |
| UY31574A1 (es) | Vacunas contra la malaria | |
| CN104056266A (zh) | 新喋呤佐剂及含新喋呤佐剂的疫苗 | |
| Lee et al. | Effect of apoptosis‐associated speck‐like protein containing a caspase recruitment domain on vaccine efficacy: Overcoming the effects of its deficiency with aluminum hydroxide adjuvant | |
| WO2018056528A3 (ko) | 인플루엔자 b 백신 | |
| RU2015115520A (ru) | Рекомбинантная вакцина для профилактики вирусного гепатита В (Варианты) | |
| CN103751777B (zh) | 甘草酸二铵佐剂及含甘草酸二铵佐剂的疫苗 | |
| Bijani et al. | Comparison of the efficacy of hepatitis B vaccination by different routes of immunization |